Ipamorelin Side Effects: Rare But Serious Adverse Events

What serious harm has actually been documented in people?

The published human evidence is a phase 2 trial in adults recovering from bowel resection and a small pharmacokinetic study in healthy volunteers [2][4]. Only the trial reports safety in a way that lets you count events. One hundred seventeen patients were enrolled and 114 were analyzed; they received 0.03 mg/kg of ipamorelin intravenously twice daily, or placebo, from postoperative day 1 to day 7 or discharge [2].

Any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group [2].

Serious adverse events occurred in 17.9% of ipamorelin-treated patients and 15.5% of placebo patients. Two ipamorelin-treated patients died of surgical complications: bowel surgery for colon cancer with an anastomotic leak. The FDA said it is unclear whether the deaths were related to ipamorelin, but that they raise safety concerns [1]. Development was reportedly discontinued after disappointing phase 2 results [1].

Other events reported more often than on placebo

The FDA's summary of the same trial lists low potassium in 12.5% of ipamorelin patients versus 3.4% on placebo, insomnia in 10.7% versus 5.2%, and high blood sugar at discharge in 14.3% versus 8.6% [1]. Low potassium and high blood sugar were reported more often with ipamorelin than with placebo.

The trial also missed its main endpoint: median time to first tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, p=0.15, and secondary gut-recovery endpoints did not differ [2].

What risks does the FDA associate with growth hormone stimulation?

Ipamorelin is a five-amino-acid peptide that raises growth hormone by acting at the ghrelin/GH-secretagogue receptor rather than the GHRH receptor [5][1]. The FDA's stated concern is that, because ipamorelin stimulates the GH and IGF-1 axis, it may carry the risks listed on approved growth hormone labels: neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism, pancreatitis and others. Like the approved GH stimulator macimorelin, it may also prolong the QT interval. The agency added that it found no data showing ipamorelin would not carry those risks [1].

These are possible class risks, not events counted in ipamorelin users.

Could it trigger an immune reaction?

FDA lists ipamorelin acetate among bulk substances that raise significant safety risks for compounding by outsourcing facilities. One stated concern is immunogenicity: FDA says aggregation and peptide-related impurities may increase the risk of an immune reaction with certain routes of administration [3]. The agency also notes that ipamorelin contains unnatural amino acids, which complicate characterizing the substance [3].

In the same entry, FDA refers to a published study that identified serious adverse events including death when ipamorelin was administered intravenously to improve gastric motility, and states that it has not identified safety-related information for other injectable routes [3]. That is a statement about what the agency had seen, not a finding that other routes are safe.

Is ipamorelin's hormone selectivity shown in people?

The selectivity claim comes mainly from animal work. In the 1998 paper that introduced the peptide, ipamorelin released growth hormone in rats and swine with potency similar to GHRP-6, and in swine none of the GH secretagogues tested affected FSH, LH, prolactin or TSH plasma levels [5].

The human studies reported growth hormone concentrations, adverse events, potassium and glucose [2][4]. The selectivity findings are from swine.

What do the human dosing and pharmacokinetic data cover?

Both published human studies used intravenous dosing: the 0.03 mg/kg twice-daily regimen in the ileus trial [2] and single 15-minute infusions ranging from 4.21 to 140.45 nmol/kg in healthy male volunteers [4]. In those volunteers, ipamorelin had a terminal half-life of about 2 hours and produced a single GH peak roughly 0.67 hours after the infusion, falling to negligible levels at every dose tested [4]. No FDA-approved dose exists [1].

FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [1]. That is an absence of data, not a finding of safety.

Regulatory status

Ipamorelin is not an FDA-approved drug, is not a component of any FDA-approved product, and has no US Pharmacopeia monograph [1]. It has been in FDA's category 2 for outsourcing facilities since September 29, 2023 and is still listed there [3][6].

The pharmacy-side picture is easy to misread. For state-licensed pharmacies, ipamorelin appears in the 'nominated but withdrawn' table and in none of the three categories on FDA's list updated May 14, 2026, and the agency's category 1 policy does not apply to it [3][7]. FDA's reviewers proposed that ipamorelin not be added to the pharmacy bulks list, and on October 29, 2024 the Pharmacy Compounding Advisory Committee voted 0 yes, 12 no, 1 abstention on both ipamorelin free base and ipamorelin acetate, citing a lack of information supporting safety and efficacy [8]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].